The 8^th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum

SABPA FTD annually brings together the latest in groundbreaking research, cutting-edge drugs, and industry trends within the biopharma sector. The event's broad spectrum of topics provides a platform for local biotech companies to engage in vibrant discussions and valuable networking opportunities. The forthcoming 8^th FTD Conference is set to shine a spotlight on three revolutionary domains in the field of metabolism disease and oncology: Glucagon-like peptide-1 (GLP-1), Antibody-Drug Conjugates (ADC), and Minimal Residual Disease (MRD), each representing the forefront of innovations in therapeutics and diagnostics.

Date and Time: March 23, 2024, 8:00 am - 5:00 pm

Location: Hilton San Diego/Del Mar 15575 Jimmy Durante Boulevard Del Mar, CA 92014

Medicilon GLP-1 New Drug R&D Service

In the formulation of GLP-1 integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of June 2023, Medicilon has successfully assisted in the clinical approval of 8 GLP-1 drugs (3 approved by FDA and NMPA，1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.

Medicilon ADC R&D Service Platform

In the formulation of ADC preclinical integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of the end of 2023, Medicilon has successfully assisted in the clinical approval of 23 ADC drugs and has 20+ ADC projects under development.

Meet with Medicilon

Subject丨SABPA FTD Forum

Name *

Work Email *

Company *

Title*

Verification Code